Dako, an Agilent Technologies Company, Announces Expanded Collaboration with Amgen Within Companion Diagnostics

March 24, 2015

The expanded collaboration will allow both companies to benefit from knowledge-sharing within the field of drug-diagnostic research and development.

PRESS RELEASE

GLOSTRUP, Denmark, March 24, 2015 (GLOBE NEWSWIRE) -- Dako, an Agilent

Technologies company and a worldwide provider of cancer diagnostics,

today announced a new Master Collaboration Agreement with Amgen Inc., a

leading biotechnology company.

The expanded collaboration will allow both companies to benefit from

knowledge-sharing within the field of drug-diagnostic research and

development in general, and in relation to companion diagnostic

products in particular. This collaboration is important in the area of

personalized medicine, where targeted treatments and companion

diagnostics can help identify patients for whom a particular treatment

may work, leading to improved patient care and more manageable

healthcare costs.

"We are proud to both continue and broaden our multi-year partnership

with Amgen," said Jacob Thaysen, president of Agilent's Diagnostics and

Genomics Group. "Together we will continue our work in the development

of high-quality companion diagnostic products to enable physicians and

pathologists to identify cancer patients who are more likely to respond

to a specific therapy."

Today's announcement follows several other collaborative agreements in

the companion diagnostics area. Agilent's Dako business has

partnerships with several top-tier pharma companies for the development

of companion diagnostics. Its track record and experience in companion

diagnostic development continues to attract new partners, as well as

add new projects with current partners.

The financial details of the agreement were not disclosed.

About Agilent Technologies and Dako Agilent Technologies Inc. (NYSE:A),

a global leader in life sciences, diagnostics and applied chemical

markets, is the premier laboratory partner for a better world. Agilent

works with customers in more than 100 countries, providing instruments,

software, services and consumables for the entire laboratory workflow.

Agilent generated revenues of $4.0 billion in fiscal 2014. The company

employs about 12,000 people worldwide. In 2012, Agilent acquired Dako,

a well-known provider of reagents, instruments, software and expertise

to make accurate diagnoses and determine the most effective treatment

for cancer patients. Information about Agilent is available at

www.agilent.com

and information about Dako is available at

www.dako.com

.